We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Chinese biopharmaceutical company BeiGene is refusing to dissolve its Abraxane cancer drug deal with Bristol Myers Squibb (BMS), saying that the U.S. company’s proposed pull-out deal is just an attempt to stem potential arbitration costs, according to a new filing with the Securities and Exchange Commission (SEC). Read More
Sanofi said that supply for all four formulations of Kevzara ― 150 mg, 200 mg, prefilled syringe and auto-injector ― are expected to be limited until early 2022 based on current projections. Read More
Pacira BioSciences will pay close to $427.5 million to buy pain management company Flexion Therapeutics, maker of Zilretta, a nonopioid injection approved in 2017 for chronic osteoarthritis. Read More
In the second announcement this week of a large drugmaker acquiring a rare diseases-focused company, Merck has agreed to buy Accleron Pharma for $11.5 billion to strengthen its cardiovascular pipeline. Read More
The companies said their method enlarges the number of possible antigen targets, which could lead to cancer immunotherapies for a broader range of patients and cancer types. Read More